Tous Actualités
Suivre
Abonner sanofi-aventis Group

sanofi-aventis Group

Sanofi Pasteur Announces Agreement to License Novel Adjuvant From Eisai Co., Ltd

Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire)

Sanofi pasteur, the vaccines business of the sanofi-aventis Group
(NYSE: SNY), has entered into an agreement with Eisai Co., Ltd. to
license their novel adjuvant, E6020, for use in the development of
new vaccines to treat or prevent human illnesses. E6020 is a
chemically synthesized adjuvant that will be tested by sanofi pasteur
to determine its ability to enhance the immune response to a broad
range of vaccines.
Under the terms of the agreement, Eisai will provide a license to
sanofi pasteur to incorporate the E6020 adjuvant for use in vaccines
throughout all geographical regions. In return Eisai will receive
upfront payments, milestone payments, and royalty payments on product
sales. Sanofi pasteur will commercialize the adjuvanted vaccines
developed in this collaboration. Further financial details of the
agreement are not disclosed.
This contract is part of sanofi pasteur's ongoing corporate
commitment to protect and improve human health worldwide by providing
superior, innovative vaccines for the prevention and treatment of
disease.
About sanofi-aventis
The sanofi-aventis Group is the world's third-largest
pharmaceutical company, ranking number one in Europe. Backed by a
world-class R&D organization, sanofi-aventis is developing leading
positions in seven major therapeutic areas: cardiovascular disease,
thrombosis, oncology, metabolic diseases, central nervous system,
internal medicine, and vaccines. The sanofi-aventis Group is listed
in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi pasteur, the vaccines business of the sanofi-aventis Group,
sold nearly a billion doses of vaccine in 2004, making it possible to
protect more than 500 million people across the globe, which is about
1.4 million per day. The company offers the broadest range of
vaccines, providing protection against 20 bacterial and viral
diseases. For more information, please visit: www.sanofipasteur.com
Forward Looking Statements
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are statements that are not historical
facts. These statements include financial projections and estimates
and their underlying assumptions, statements regarding plans,
objectives and expectations with respect to future operations,
products and services, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expect," "anticipates," "believes," "intends," "estimates," "plans"
and similar expressions. Although sanofi-aventis' management believes
that the expectations reflected in such forward-looking statements
are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of sanofi-aventis, that could cause actual results
and developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include those discussed or
identified in the public filings with the SEC and the AMF made by
sanofi-aventis, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended
December 31, 2004. Other than as required by applicable law,
sanofi-aventis does not undertake any obligation to update or revise
any forward-looking information or statements.
Sanofi-aventis Group subsidiaries in the United States include
Sanofi-Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi
Pasteur Inc.
Contact:
    sanofi pasteur                          sanofi pasteur
    Alain BERNAL                            Len LAVENDA
    Vice-President Corporate Communications U.S. Media Relations
    Tel: + 33-(0)4-37-37-78-97              Tel: +1-570-839-4446
    Fax: +33-(0)4-37-37-77 89                Len.Lavenda@sanofipasteur.com

Contact:

Contact: sanofi pasteur, Alain BERNAL, Vice-President Corporate
Communications, Tel: + 33-(0)4-37-37-78-97, Fax: +33-(0)4-37-37-77
89; sanofi pasteur, Len LAVENDA, U.S. Media Relations, Tel:
+1-570-839-4446, Len.Lavenda@sanofipasteur.com

Plus de actualités: sanofi-aventis Group
Plus de actualités: sanofi-aventis Group